Special Drug Use-results Surveillance of Tabrecta Tablets
Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced/Recurrent Non-small Cell Lung Cancer)
ClinicalTrials.gov Identifier: NCT04575025
Novartis Reference Number: CINC280AJP01
Last Update: Nov 25, 2022
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
This study is an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance. As an all-case study, this study will collect all patients treated with Tabrecta in a specified post-marketing period. The observation period of each patient is up to 1 year (52 weeks)
Interventions
Eligibility Criteria
Inclusion Criteria:
All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period
Exclusion Criteria:
-
Study Locations
Contacts
Have a question?
Call 1-888-669-6682 or email [email protected]